The sanofi-aventis Group thanks its team members and shareholders and launches its new visual identity

The sanofi-aventis Group thanks its team members and shareholders and launches its new visual identity (Paris, September 16, 2004) The sanofi-aventis Group launched an advertising campaign today in France, Germany and internationally to thank its team members and shareholders for their help in the creation of the world's 3rd largest pharmaceutical group. « Thank you to the 100 000 team members and shareholders who helped create the 3rd largest pharmaceutical company in the world" The campaign also publicly reveals the new visual identity of the new Group, its logo, which will symbolise this new human endeavour around the world. The new logo brings to mind the overriding goal that each and every member of the Group shares: improving health. Graphically, the logo block shows our willingness to move forward together with a shared vision of the profession that unites us. It places all humanity, each and every individual, at the very heart of our vocation and commitments. This logo consists of a symbol, a logo block, and a signature. - The symbol speaks to the heart of mankind and expresses solidarity. - The perfectly balanced, all-embracing curved line underscores the typo block of the sanofi-aventis name and symbolises people joining together. Its colour and rounded shape express humanistic values as well as the environment of scientific expertise in which we live. - Finally, the signature, « Because health matters », reminds all of us of our vocation and our commitment to enable the greatest number of people to gain access to medicines. Yesterday, on September 15, 2004, the new visual identity was launched and presented to all the 100,000 team members of the sanofi-aventis Group around the world. On every site, internal meetings were organised to reveal the logo to all team members. At the corporate Headquarters, the internal meeting was chaired by Jean-François DEHECQ. Further to the birth of the sanofi-aventis Group on August 20, 2004, and to the announcement in early September of the appointment of a hundred managers throughout the world, a new milestone has been reached in the integration process of the new Group. The sanofi-aventis Group is the world's 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, vaccines. Important Information In connection with its acquisition of Aventis, Sanofi-Aventis has announced that it is studying the feasibility of merging Aventis with and into Sanofi-Aventis, with Sanofi-Aventis continuing as the surviving corporation. In connection with any merger of Aventis into Sanofi-Aventis, Sanofi-Aventis will file a post-effective amendment to its registration statement on Form F-4 (File no. 333-112314), which will include a prospectus relating to the merger, and will file additional documents with the SEC. Investors are urged to read the registration statement, including any preliminary prospectus or definitive prospectus (when available) relating to the merger, and any other relevant documents filed with the SEC, including all amendments and supplements, because they will contain important information. Free copies of the registration statement, as well as other relevant documents filed with the SEC, may be obtained at the SEC's web site at www.sec.gov. At the appropriate time, Sanofi-Aventis will provide investors with information on how to obtain any merger-related documents for free from Sanofi-Aventis or from its duly appointed agents. ------------------------------------------------------------ Informasjonen er sendt gjennom Waymaker http://www.waymaker.no Nedenstående filer kan lastes ned: http://www.waymaker.net/bitonline/2004/09/16/20040916BIT20030/wkr0001.pdf Pressemeldingen i pdf-format

Om oss

Et stort farmasøytisk selskap som setter fokus på helse over hele verden. Med en nettoomsetning i 2004 på 26 750 millioner euro, og mer enn 100 000 ansatte i rundt 100 land er Sanofi-aventis er et av verdens ledende legemiddel selskap og er blant topp 6 i Norge. Det globale hovedkontoret er i Paris, Frankrike. Det norske hovedkontoret befinner seg på Lysaker. 7 viktige behandlingsområder Sanofi-aventis fokuserer sine aktiviteter på 7 viktige behandlingsområder: Hjerte-karsykdommer (f. eks. Hypertensjon)Thrombose (Blodpropp)Onkologi (Kreft)Sykdommer i sentralnervesystemet (f.eks. MS) DiabetesOsteoporose (Benskjørhet) Gode legemidler for millioner av pasienter Sanofi-aventis’ portefølje av markedsførte produkter inkluderer flere legemidler som er verdensledere i sine respektive klasser, innen områdene blodpropp, hjerte-karsykdommer, søvnforstyrrelser, epilepsi, diabetes og kreft. Svært produktiv og nyskapende forskning og utvikling Grunnlaget for sanofi-aventis' verdensomspennende fremgang er en svært produktiv og nyskapende forsknings- og produktutviklingsorganisasjon med rundt 11 000 forskere som jobber i mer enn 20 forskningssentere på tre kontinenter. Her legger vi vekt på å forske frem nyskapende terapeutiske behandlinger. For øyeblikket er rundt tretti forsknings- og produktutviklingsprosjekter kommet meget langt i utviklingen. Se forøvrig hjemmesiden til Legemiddelindustriforeningen. For mer informasjon om sanofi-aventis rundt om i verden kan du besøke www.sanofi-aventis.com.

Abonner

Dokumenter og linker